Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Lantheus Holdings, Inc. regarding a class action lawsuit due to alleged false statements and concealment of information related to the company's revenue outlook and market dynamics [1][2]. Summary by Sections Allegations - The complaint alleges that Lantheus Holdings made false statements and concealed information that misled investors about the company's projected revenue and growth potential. Specifically, it is claimed that the company downplayed risks associated with competition, pricing dynamics, seasonality, and macroeconomic fluctuations. The optimistic reports regarding Pylarify's sales growth and pricing normalization were found to be inaccurate [1]. Class Action Details - The class period for the lawsuit is defined as February 26, 2025, to August 5, 2025. Shareholders who purchased shares during this period are encouraged to register for participation in the class action [1][2]. - The deadline for shareholders to seek lead plaintiff status is November 10, 2025. There is no cost or obligation for shareholders to participate in the case [2]. Firm's Mission - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors who have suffered losses due to deceit, fraud, and illegal business practices. The firm aims to ensure that companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements [3].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Lantheus Holdings, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Lantheus securities between February 26, 2025, and August 5, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by November 10, 2025 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Case Allegations - The lawsuit alleges that Lantheus provided misleading statements regarding the competitive position of its product, Pylarify, while concealing material adverse facts [5]. - It is claimed that Lantheus failed to properly assess pricing and competitive dynamics, which risked Pylarify's price point, revenue, and growth potential [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Lantheus Holdings, Inc. due to misleading statements regarding the competitive position of its product Pylarify, which led to significant financial losses for investors [4][6]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in Lantheus between February 26, 2025, and August 5, 2025, to discuss their legal options [1][4]. - There is a deadline of November 10, 2025, for investors to seek the role of lead plaintiff in a federal securities class action against Lantheus [4]. Group 2: Financial Performance and Impact - Lantheus reported disappointing first-quarter results on May 7, 2025, with Pylarify's performance falling short of market expectations [7]. - On August 6, 2025, Lantheus announced further disappointing results, reducing growth expectations for Pylarify, which had declined by 8.3% year-over-year, and slashed fiscal year 2025 growth projections [7]. - Following these announcements, Lantheus' stock price plummeted from $72.83 per share on August 5, 2025, to $51.87 per share on August 6, 2025, marking a decline of approximately 28.8% in one day [8]. Group 3: Investor Actions - Investors and analysts reacted swiftly to the negative revelations about Lantheus, leading to a significant drop in the company's stock price [8]. - The lead plaintiff in a class action is defined as the investor with the largest financial interest who directs the litigation on behalf of the class [9].

Core Viewpoint - The Lantheus Holdings, Inc. class action lawsuit alleges that the company and its executives misled investors regarding the company's revenue outlook and growth potential, particularly concerning its key product, Pylarify, which is used in prostate cancer diagnosis and treatment [1][3]. Group 1: Allegations and Financial Impact - The lawsuit claims that Lantheus created a false impression of having reliable information about its projected revenue and growth while downplaying risks from competition and market dynamics [3]. - On May 7, 2025, Lantheus reported a year-over-year decrease in Pylarify sales and reduced its full-year growth projections from low-single-digit to mid-single-digit growth to flat-to-low single-digit growth, resulting in a stock price drop of over 23% [4]. - On August 6, 2025, Lantheus announced further disappointing results, with Pylarify sales down 8.3% year-over-year, leading to a nearly 29% decline in stock price after slashing fiscal year 2025 growth projections [5]. Group 2: Legal Process and Representation - Investors who purchased Lantheus securities during the class period (February 26, 2025, to August 5, 2025) can seek appointment as lead plaintiff in the class action lawsuit, which allows them to act on behalf of other class members [6]. - The lead plaintiff can choose a law firm to represent the class, and participation as lead plaintiff does not affect an investor's ability to share in any potential recovery [6]. Group 3: Company Overview - Lantheus develops, manufactures, and commercializes diagnostic and therapeutic products for heart, cancer, and other diseases, with Pylarify being a key product in its portfolio [2].

Core Viewpoint - A securities class action lawsuit has been filed against Lantheus Holdings, Inc. for allegedly making false and misleading statements regarding its product PYLARIFY and its competitive position during the specified class period from February 26, 2025, to August 5, 2025 [1][2]. Allegations of Misconduct - The lawsuit claims that Lantheus misled investors about PYLARIFY's competitive position, failing to properly assess pricing and competitive dynamics [2]. - It is alleged that Lantheus did not disclose that a price increase in early 2025, despite previous price erosion, created opportunities for competitive pricing, jeopardizing PYLARIFY's price point and revenue potential [2]. - The complaint asserts that the public statements made by Lantheus were materially false and misleading throughout the class period [2]. Lead Plaintiff Process - Investors in Lantheus have until November 10, 2025, to seek appointment as a lead plaintiff representative in the class action [3]. - A lead plaintiff acts on behalf of all class members and is typically the investor or group of investors with the largest financial interest [3]. - The decision to serve as a lead plaintiff does not affect an investor's ability to share in any recovery from the lawsuit [3]. Firm Background - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has a reputation for recovering billions for victims of corporate misconduct [4]. - The firm encourages Lantheus investors who have suffered losses to contact them for more information [4].

Core Viewpoint - A class action lawsuit has been filed against Lantheus Holdings, Inc. for allegedly making materially false and misleading statements regarding its product Pylarify and its competitive position during the class period from February 26, 2025, to August 5, 2025 [3][7]. Allegation Details - The lawsuit claims that Lantheus provided overly positive statements while concealing adverse facts about Pylarify's competitive position [3]. - It is alleged that the company was not adequately equipped to assess pricing and competitive dynamics for Pylarify [3]. - The complaint states that a price increase in early 2025, despite previous price erosion, created opportunities for competitive pricing, jeopardizing Pylarify's price point, revenue, and growth potential [3]. - As a result, the statements made by the defendants regarding the company's business and prospects were materially false and misleading [3]. Next Steps - Investors who purchased Lantheus shares and suffered losses are encouraged to contact the law firm for more information and to discuss their rights [4][7]. - There is no cost or obligation for investors to inquire about their claims [4]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in complex litigation [5]. - The firm has offices in New York, California, and South Carolina and handles cases in state and federal courts across the country [5].

Core Points - A shareholder has filed a securities class action lawsuit on behalf of investors who purchased or acquired Lantheus Holdings, Inc. securities between February 26, 2025, and August 5, 2025 [1] - The lawsuit alleges that the defendants made misrepresentations regarding the competitive position of Lantheus' key Radiopharmaceutical Oncology product, Pylarify [2] Legal Proceedings - Investors wishing to serve as lead plaintiff must file papers by November 10, 2025, and representation is on a contingency fee basis, meaning shareholders pay no fees or expenses [3] - The law firm Bernstein Liebhard LLP has a history of recovering over $3.5 billion for clients and has been recognized for its success in litigating class actions [4]

Core Viewpoint - A class action securities lawsuit has been filed against Lantheus Holdings, Inc. for alleged securities fraud affecting investors between February 26, 2025, and August 5, 2025 [1][2] Group 1: Lawsuit Details - The lawsuit claims that Lantheus made false statements and concealed information regarding its revenue outlook and growth potential, particularly related to the sales growth of its product Pylarify [2] - Allegations include that Lantheus misrepresented its understanding of market dynamics, including competition, pricing, seasonality, and macroeconomic factors [2] Group 2: Investor Information - Investors who suffered losses during the specified period have until November 10, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing significant settlements for shareholders and is recognized as one of the top securities litigation firms in the United States [4]

Core Viewpoint - Investors in Lantheus Holdings, Inc. have the opportunity to lead a securities fraud class action lawsuit due to alleged misleading statements regarding the company's market understanding and business prospects [1][2]. Summary by Relevant Sections Lawsuit Details - The lawsuit claims that from February 26, 2025, to August 5, 2025, Lantheus failed to disclose critical information about its understanding of the pricing and competitive dynamics of the Pylarify market [2]. - The complaint asserts that the positive statements made by the defendants regarding the company's business operations and future prospects were materially misleading and lacked a reasonable basis [2]. Participation Information - Investors who suffered losses on their Lantheus investments are encouraged to participate in the lawsuit, with a lead plaintiff deadline set for November 10, 2025 [2]. - Interested parties can contact Glancy Prongay & Murray LLP for more information or to learn about their rights regarding the lawsuit [3][4].

Core Viewpoint - A class action securities lawsuit has been filed against Lantheus Holdings, Inc. for alleged securities fraud affecting investors between February 26, 2025, and August 5, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made false statements and concealed information regarding the company's revenue outlook and growth potential, particularly related to Pylarify's sales growth and market dynamics [2]. - It is alleged that Lantheus did not accurately understand the pricing and competitive dynamics of Pylarify's market, contrary to the optimistic reports provided by the company [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until November 10, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, indicating no financial obligation to participate in the lawsuit [3]. Group 3: Law Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].